AFP
INSY

Ausdal Financial Partners’s Insys Therapeutics, Inc. INSY Stock Holding History

Ausdal Financial Partners’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,232
Closed -$35K – 1162
2015
Q4 		$35K Buy
+1,232
New +$34.1K 0.02% 560

Other funds holding INSY

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FHAM
Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GAM
Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Ausdal Financial Partners's INSY Position: Q1 2016 in Review

Ausdal Financial Partners sold out of Insys Therapeutics, Inc. (INSY) in Q1 2016, closing a stake of 1,232 shares — an estimated $35K sold.

Ausdal Financial Partners first reported a position in INSY in Q4 2015 and held it in 1 quarter. The position peaked at $35K in Q4 2015. 138 funds tracked by Wall St. Rank hold INSY as of Q1 2016.

  • Ausdal Financial Partners reported no remaining Insys Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
  • Ausdal Financial Partners sold 1,232 Insys Therapeutics, Inc. shares in Q1 2016, an estimated $35K.
  • Ausdal Financial Partners first reported a position in Insys Therapeutics, Inc. in Q4 2015 and held it in 1 quarter.
  • Ausdal Financial Partners's Insys Therapeutics, Inc. position peaked at $35K in Q4 2015.
  • 138 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q1 2016.

Based on Ausdal Financial Partners's 13F filing for Q1 2016, filed 5 May 2016.